We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Anavex (AVXL) Run Higher on Strong Earnings Estimate Revisions?
Read MoreHide Full Article
Anavex Life Sciences Corp. (AVXL - Free Report) is a clinical stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AVXL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Anavex could be a solid choice for investors.
Current Quarter Estimates for AVXL
In the past 30 days, 1 estimate has gone higher for Anavex while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 10 cents a share 30 days ago, to a loss of 9 cents today, a move of 10%.
Current Year Estimates for AVXL
Meanwhile, Anavex’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 44 cents per share 30 days ago to a loss of 38 cents per share today, an increase of 13.6%.
The stock has also started to move higher lately, adding 12.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Anavex (AVXL) Run Higher on Strong Earnings Estimate Revisions?
Anavex Life Sciences Corp. (AVXL - Free Report) is a clinical stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AVXL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Anavex could be a solid choice for investors.
Current Quarter Estimates for AVXL
In the past 30 days, 1 estimate has gone higher for Anavex while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 10 cents a share 30 days ago, to a loss of 9 cents today, a move of 10%.
Current Year Estimates for AVXL
Meanwhile, Anavex’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 44 cents per share 30 days ago to a loss of 38 cents per share today, an increase of 13.6%.
Anavex Life Sciences Corp. Price and Consensus
Anavex Life Sciences Corp. Price and Consensus | Anavex Life Sciences Corp. Quote
Bottom Line
The stock has also started to move higher lately, adding 12.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>